High ROIC Stocks
NVS is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
NOVARTIS AG-SPONSORED ADR (NVS) Stock Price & Overview
NYSE:NVS • US66987V1098
Current stock price
153.78 USD
-0.25 (-0.16%)
Last:
The current stock price of NVS is 153.78 USD. Today NVS is down by -0.16%. In the past month the price decreased by -4.34%. In the past year, price increased by 45.52%.
NVS Key Statistics
52-Week Range97.715 - 170.46
Current NVS stock price positioned within its 52-week range.
1-Month Range145.295 - 163.08
Current NVS stock price positioned within its 1-month range.
- Market Cap
- 295.072B
- P/E
- 17.03
- Fwd P/E
- 16.92
- EPS (TTM)
- 9.03
- Dividend Yield
- 3.11%
NVS Stock Performance
Today
-0.16%
1 Week
+2.89%
1 Month
-4.34%
3 Months
+11.18%
Longer-term
6 Months +16.35%
1 Year +45.52%
2 Years +58.58%
3 Years +50.17%
5 Years +80.70%
10 Years -59.45%
NVS Stock Chart
NVS Stock Screens
NVS currently appears in the following ChartMill screener lists.
Best Dividend Stocks
NVS is currently part of our Best Dividend Stocks screen, indicating it pays a high and sustainable dividend.
Safe Dividend Stocks
NVS occurs in our Safe Dividends Stock Screen, indicating it has a high and sustainable dividend, while being financially healthy
Dividend Growth Stocks
NVS is part of our Dividend Growth Stocks screen, indicating it has a reliable dividend with grows strongly
NVS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NVS. When comparing the yearly performance of all stocks, NVS is one of the better performing stocks in the market, outperforming 81.58% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NVS Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NVS. NVS gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVS Earnings
On February 4, 2026 NVS reported an EPS of 2.04 and a revenue of 13.34B. The company missed EPS expectations (-0.17% surprise) and missed revenue expectations (-4.89% surprise).
Next Earnings DateApr 28, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$2.04
Revenue Reported13.336B
EPS Surprise -0.17%
Revenue Surprise -4.89%
NVS Forecast & Estimates
34 analysts have analysed NVS and the average price target is 156 USD. This implies a price increase of 1.44% is expected in the next year compared to the current price of 153.78.
For the next year, analysts expect an EPS growth of 0.69% and a revenue growth 2.53% for NVS
Analysts
Analysts70.59
Price Target156 (1.44%)
EPS Next Y0.69%
Revenue Next Year2.53%
NVS Groups
Sector & Classification
NVS Financial Highlights
Over the last trailing twelve months NVS reported a non-GAAP Earnings per Share(EPS) of 9.03. The EPS increased by 14.98% compared to the year before.
Income Statements
Revenue(TTM)56.33B
Net Income(TTM)13.98B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.83% | ||
| ROA | 12.6% | ||
| ROE | 30.31% | ||
| Debt/Equity | 0.64 |
Chartmill High Growth Momentum
EPS Q2Q%2.53%
Sales Q2Q%1.39%
EPS 1Y (TTM)14.98%
Revenue 1Y (TTM)8.91%
NVS Ownership
Ownership
Inst Owners41.7%
Shares1.92B
Float1.69B
Ins Owners0.03%
Short Float %0.44%
Short Ratio3.02
NVS Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.69 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.88 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.42 | 298.838B | ||
| PFE | PFIZER INC | 9.44 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.4 | 121.374B | ||
| ZTS | ZOETIS INC | 16.7 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.32 | 28.018B | ||
| VTRS | VIATRIS INC | 5.33 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.34 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVS
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
IPO: 2001-05-07
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056 CH
CEO: Vasant (Vas) Narasimhan
Employees: 75883
Phone: 41613241111
NOVARTIS AG-SPONSORED ADR / NVS FAQ
What does NOVARTIS AG-SPONSORED ADR do?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
What is the current price of NVS stock?
The current stock price of NVS is 153.78 USD. The price decreased by -0.16% in the last trading session.
What is the dividend status of NOVARTIS AG-SPONSORED ADR?
NOVARTIS AG-SPONSORED ADR (NVS) has a dividend yield of 3.11%. The yearly dividend amount is currently 4.02.
What is the ChartMill rating of NOVARTIS AG-SPONSORED ADR stock?
NVS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does NOVARTIS AG-SPONSORED ADR belong to?
NOVARTIS AG-SPONSORED ADR (NVS) operates in the Health Care sector and the Pharmaceuticals industry.
Is NOVARTIS AG-SPONSORED ADR (NVS) expected to grow?
The Revenue of NOVARTIS AG-SPONSORED ADR (NVS) is expected to grow by 2.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is NOVARTIS AG-SPONSORED ADR worth?
NOVARTIS AG-SPONSORED ADR (NVS) has a market capitalization of 295.07B USD. This makes NVS a Mega Cap stock.